Short-term Outcomes Between Robot-assisted and Open Pancreaticoduodenectomy in Patients with High Body Mass Index: A Propensity Score Matched Study
Overview
Affiliations
Background: High body mass index was considered as a risk factor for minimally invasive surgery. The short-term outcomes of robot-assisted pancreaticoduodenectomy (RPD) remain controversial. This study aims to investigate the feasibility and advantage of RPD in patients with high body mass index compared to open pancreaticoduodenectomy (OPD).
Methods: Clinical data of 304 patients who underwent pancreaticoduodenectomy from January 2016 to December 2019 in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine was collected. Patients with BMI >25 kg/m were included and divided into RPD and OPD group. After PSM at a 1:1 ratio, 75 patients of OPD and 75 patients of RPD were recorded and analyzed.
Results: The RPD group showed advantages in the estimated blood loss (EBL) (323.3 mL vs. 480.7 mL, p = 0.010), the postoperative abdominal infection rate (24% vs. 44%, p = 0.010), the incidence of Clavien-Dindo III-V complications (14.7% vs. 28.0%, p = 0.042) over OPD group.
Conclusion: RPD shows advantages in less EBL, lower incidence rate of Clavien-Dindo III-V complications over OPD in overweight and obese patients. RPD was confirmed as a safe and feasible surgical approach for overweight or obsess patients.
Waseem M, Abideen Z, Durrani R, Dilawar E, Kamran M, Butt H J Gastrointest Cancer. 2025; 56(1):57.
PMID: 39875624 DOI: 10.1007/s12029-025-01177-0.
Shyr B, Shyr B, Chen S, Wang S, Shyr Y Int J Med Robot. 2024; 20(6):e70034.
PMID: 39698987 PMC: 11656678. DOI: 10.1002/rcs.70034.
Xu S, Xu Y, Wang S, Chu Q, Zhang H, Gong W Surg Endosc. 2024; 39(2):881-890.
PMID: 39627557 DOI: 10.1007/s00464-024-11418-1.
Robotic pancreaticoduodenectomy in patients with overweight or obesity: a meta-analysis protocol.
Yang W, Zeng H, Jin Y BMJ Open. 2024; 14(7):e080605.
PMID: 39019640 PMC: 11284876. DOI: 10.1136/bmjopen-2023-080605.
Li J, Qian L, Shi Y, Shen B, Peng C Cancer Med. 2023; 12(14):15141-15148.
PMID: 37255405 PMC: 10417296. DOI: 10.1002/cam4.6186.